Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROMETHAZINE W/ CODEINE vs PROMETHAZINE VC W/ CODEINE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Codeine is a prodrug converted to morphine, a mu-opioid receptor agonist, which inhibits nociceptive transmission; promethazine is a phenothiazine derivative with H1-receptor antagonism, anticholinergic, and antiemetic effects.
Codeine is a prodrug converted to morphine, which acts as a mu-opioid receptor agonist inhibiting ascending pain pathways and altering pain perception. Promethazine is a phenothiazine derivative that antagonizes histamine H1 receptors, suppresses cough reflex via central action, and has anticholinergic, sedative, and antiemetic effects. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction of nasal blood vessels, reducing congestion.
Relief of mild to moderate pain,Cough suppression
Relief of cough and symptoms of upper respiratory infections,Allergic rhinitis,Common cold,Nasal congestion
10 m L (1 mg codeine, 6.25 mg promethazine per 5 m L) orally every 4-6 hours as needed for cough. Maximum: 60 m L per day. Do not exceed 5 days.
1-2 tablets orally every 4-6 hours as needed for cough and congestion. Maximum 12 tablets in 24 hours.
Promethazine: 10-19 hours (terminal). Codeine: 2.5-3.5 hours (terminal); prolonged in renal impairment.
Promethazine: 9-16 hours (range 7-20 hours) in adults; codeine: 2.5-3.5 hours (terminal) with clinical considerations for prolonged effects in hepatic impairment and CYP2D6 poor metabolizers.
e GFR 30-59 m L/min: Administer every 6 hours; e GFR 15-29 m L/min: Administer every 8 hours; e GFR <15 m L/min: Avoid use or consider extended interval due to accumulation of codeine metabolites.
Avoid use in severe renal impairment (e GFR <30 m L/min). For moderate impairment (e GFR 30-59 m L/min), reduce dose by 50% and monitor for CNS depression.
Warning: Risk of respiratory depression, especially in children; fatal respiratory depression can occur. Codeine is contraindicated in children <12 years and should not be used in children <18 years after tonsillectomy/adenoidectomy. Also, risk of opioid addiction, abuse, and misuse.
PROMETHAZINE W/ CODEINE is contraindicated during all trimesters. First trimester: codeine is associated with increased risk of congenital malformations (cardiac, cleft palate) due to opioid receptor activation. Promethazine may cause mild neural tube defects. Second/third trimesters: codeine can cause fetal opioid dependence and neonatal abstinence syndrome; promethazine may cause respiratory depression and thrombocytopenia in neonates. Chronic use may lead to preterm birth and low birth weight. Do not use during labor and delivery due to risk of respiratory depression in the neonate.
PROMETHAZINE: First trimester - limited data, avoid; second/third trimester - associated with maternal respiratory depression and neonatal withdrawal. CODEINE: First trimester - crosses placenta, risk of neural tube defects?; second/third trimester - neonatal opioid withdrawal syndrome, respiratory depression. Combination: Avoid in all trimesters unless benefit outweighs risk.
Promethazine with codeine is contraindicated in children <6 years due to risk of fatal respiratory depression. Avoid in patients with asthma or COPD. Use with caution with other CNS depressants. Monitor for signs of serotonin syndrome if combined with serotonergic drugs.
Promethazine VC w/ Codeine is a fixed-dose combination containing promethazine (antihistamine/antiemetic), phenylephrine (decongestant), and codeine (opioid antitussive). It is indicated for cough and upper respiratory symptoms. Due to codeine's prodrug nature (CYP2D6 conversion to morphine), avoid in children <12 years and in CYP2D6 ultra-rapid metabolizers due to risk of life-threatening respiratory depression. Monitor for anticholinergic effects (promethazine) and hypertension (phenylephrine). Use with caution in asthma, COPD, or other respiratory compromise.
No interactions on record
No interactions on record
PROMETHAZINE W/ CODEINE and PROMETHAZINE VC W/ CODEINE are distinct pharmacological agents. PROMETHAZINE W/ CODEINE belongs to the Antihistamine / Antiemetic class and is primarily used for Relief of mild to moderate painCough suppression. PROMETHAZINE VC W/ CODEINE belongs to the Antihistamine / Antiemetic class and is primarily used for Relief of cough and symptoms of upper respiratory infectionsAllergic rhinitisCommon coldNasal congestion. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. PROMETHAZINE W/ CODEINE carries a safety status of Category A/B, whereas PROMETHAZINE VC W/ CODEINE safety is classified as Category A/B. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Codeine: Hepatic via CYP2D6 (to morphine), CYP3A4 (to norcodeine); Promethazine: Hepatic via CYP2B6, CYP2D6, and glucuronidation.
Codeine is metabolized primarily by CYP2D6 to morphine (active) and by CYP3A4 to norcodeine. Promethazine is metabolized by oxidation in the liver via CYP2D6 and other pathways, with sulfoxidation and N-demethylation. Phenylephrine is metabolized mainly by monoamine oxidase (MAO) in the liver and intestinal wall.
Promethazine: renal (70% as metabolites, <1% unchanged), fecal (20-30%). Codeine: renal (90%, of which 5-10% unchanged, rest as metabolites), fecal (minor).
Renal: 70-80% as unchanged promethazine and metabolites (including codeine and its glucuronides); biliary/fecal: 10-20%.
Promethazine: 93% (primarily to albumin). Codeine: 7-25% (to albumin).
Promethazine: 93% bound primarily to albumin; codeine: 7-25% bound to albumin.
Promethazine: 5-14 L/kg (extensive tissue distribution). Codeine: 3-6 L/kg (widely distributed).
Promethazine: Vd ~14 L/kg (large distribution into tissues, CNS penetration); codeine: Vd ~3-6 L/kg.
Promethazine: oral 25% (due to first-pass metabolism), IM ~88%. Codeine: oral 50-70% (converted to morphine via CYP2D6), IM ~80%.
Oral: 25-30% for promethazine (extensive first-pass metabolism); codeine: 50-70% oral (variable due to CYP2D6 metabolism).
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50% or extend interval; Child-Pugh C: Avoid use due to risk of hepatic encephalopathy and impaired codeine metabolism.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), reduce dose by 50% and extend dosing interval.
Use not recommended in children <12 years due to risk of respiratory depression. For ages 12-18: 10-15 m L (with caution) every 4-6 hours as needed. Weight-based dosing: 0.5-1 mg/kg/dose of codeine (max 60 mg/day) with promethazine 0.25-0.5 mg/kg/dose (max 25 mg/dose).
Not recommended for children under 6 years. For children 6-11 years: 1/2 to 1 tablet orally every 4-6 hours, maximum 6 tablets in 24 hours. For children ≥12 years: same as adult dose.
Initiate with 5 m L orally every 6-8 hours; titrate cautiously due to increased sensitivity, risk of sedation, and anticholinergic effects. Maximum daily dose: 40 m L. Avoid in patients with significant cognitive impairment.
Start with lowest effective dose (1 tablet) every 4-6 hours. Monitor for CNS depression, confusion, and constipation. Avoid in patients with significant renal or hepatic impairment.
Codeine is contraindicated for post-operative pain management in children who have undergone tonsillectomy and/or adenoidectomy. It is contraindicated in children younger than 12 years of age for cough and pain. Use in children under 18 years with risk factors for respiratory depression is not recommended. Concomitant use with CYP3A4 inhibitors may result in fatal respiratory depression.
Respiratory depression, risk of opioid-induced hyperalgesia, severe hypotension, seizures in patients with porphyria, sedation and impaired motor skills, risk of serotonin syndrome when combined with serotonergic drugs, avoid abrupt discontinuation, use caution in elderly, hepatic/renal impairment, and respiratory disorders.
Hypersensitivity to codeine, promethazine, or any phenothiazine; children <12 years; postoperative management in children <18 years following tonsillectomy/adenoidectomy; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; concurrent use of MAOIs or within 14 days.
Avoid alcohol; may enhance sedative effects. No specific food restrictions, but high-fat meals may delay absorption.
Avoid grapefruit or grapefruit juice as it may increase codeine levels. Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products) due to phenylephrine's potential to cause hypertensive crisis. Limit caffeine intake as it may increase adverse effects. No specific restrictions with other foods.
Breastfeeding not recommended. Codeine is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 2.5-3.0 (for morphine, codeine active metabolite). In mothers who are CYP2D6 ultra-rapid metabolizers, codeine can lead to life-threatening respiratory depression in infants. Promethazine is excreted in low amounts but may cause sedation and apnea in neonates.
PROMETHAZINE: Excreted in breast milk (M/P ratio not established); use caution, may cause drowsiness or apnea in infants. CODEINE: Excreted in breast milk (M/P ratio 1:2.5); risk of infant opioid toxicity due to CYP2D6 variability. Contraindicated in breastfeeding unless urgent.
Pregnancy is a contraindication; thus, dosing adjustments are not applicable. If unavoidable, use the lowest effective dose for the shortest duration, but no safe dose established. Avoid during third trimester due to risk of neonatal respiratory depression. Codeine pharmacokinetics in pregnancy: increased clearance due to enhanced hepatic blood flow and CYP2D6 induction, but this is not a basis for dose adjustment as risk outweighs benefit.
No specific pharmacokinetic studies in pregnancy. General pharmacokinetic changes include increased volume of distribution and hepatic metabolism in late pregnancy, potentially requiring dose adjustment. Use lowest effective dose for shortest duration. Avoid in third trimester for codeine due to risk of neonatal withdrawal.
May cause drowsiness; avoid driving or operating machinery.,Do not exceed recommended dose; risk of addiction and dependence.,Do not consume alcohol while taking this medication.,Take with food if gastrointestinal upset occurs.,Stop use and seek medical attention if breathing becomes difficult or you experience rash.
Do not exceed recommended dose due to risk of severe respiratory depression.,Avoid alcohol and other central nervous system depressants.,May cause drowsiness; avoid driving or operating heavy machinery.,Do not use in children under 12 years or if breastfeeding.,Stop and seek medical attention if you have slow or shallow breathing, confusion, or severe dizziness.,Take with food if stomach upset occurs.,Do not use for longer than prescribed due to risk of dependence.